Why medical device manufacturers need regulatory and quality expertise when using AI in the United States, Canada, the United Kingdom, and the European Union
A recent talk I attended at AdvaMed’s The MedTech Conference in Boston, held October 18–21, 2026, prompted an important question: Are medical device companies becoming too comfortable relying on artificial intelligence to prepare regulatory submissions and quality management system documentation?
The attraction is understandable. AI can generate a procedure in seconds, organize technical information, and turn rough notes into polished language. For companies facing tight budgets and aggressive development timelines, those capabilities can be valuable.
But polished language is not proof of compliance.
A regulatory submission must accurately represent your device and the evidence supporting it. A quality management system (QMS) must reflect processes your organization actually implements, maintains, and monitors. Neither becomes compliant simply because the documents sound convincing.
AI can support this work. Qualified regulatory and quality professionals must direct it, verify it, and determine whether the result is fit for its intended purpose.
Generative AI can produce inaccurate statements, unsupported conclusions, and references that appear credible but do not withstand verification. NIST identifies this risk—often called “hallucination” or “confabulation”—in its guidance on generative AI risk management.
In regulatory work, these errors can be difficult to spot. An AI-generated document might reference an outdated requirement, apply the wrong classification rule, misinterpret a guidance document, or describe testing that your company has not performed.
Consider a hypothetical submission that states a software risk control has been verified. The sentence reads well. However, the cited test report covers an earlier software version and does not test that control.
The wording is clear. The evidence is insufficient.
An experienced reviewer examines the connection between the claim, the requirement, the device configuration, and the supporting record. That is where regulatory judgment matters—and where relying on AI alone can create significant exposure.
International alignment does not make regulatory requirements interchangeable. A shared foundation, such as ISO 13485, does not eliminate national requirements or differences in market access.
FDA’s Quality Management System Regulation (QMSR) became effective on February 2, 2026. It incorporates ISO 13485:2016 by reference into 21 CFR Part 820 while retaining additional FDA requirements. An ISO 13485 certificate alone does not establish compliance with all applicable FDA obligations.
An AI-generated QMS based on outdated source material may still rely on the former regulatory structure. A generic ISO-based system may also overlook U.S.-specific obligations.
Submission preparation presents another challenge: the correct pathway, supporting evidence, and regulatory rationale depend on the device. Experts must evaluate whether the proposed claims are supported and whether the submission accurately reflects the product being brought to market.
For Class II, III, and IV medical devices, Canada’s licensing framework includes applicable ISO 13485 quality management system certification requirements. Health Canada uses the Medical Device Single Audit Program (MDSAP) for the relevant manufacturer QMS certification framework.
Generating an ISO 13485 procedure manual does not establish MDSAP readiness. A manufacturer needs implemented processes, appropriate records, and evidence that its system addresses applicable Canadian requirements.
A submission assembled from generic material may also fail to distinguish between device classes and their evidence requirements. Experienced review helps connect classification, licensing strategy, supporting data, and the quality system.
A regulatory strategy for the United Kingdom must distinguish Great Britain from Northern Ireland. Great Britain operates under its applicable UK framework, while EU MDR and IVDR requirements apply in Northern Ireland. MHRA guidance also addresses registration, UK Responsible Persons, and conditions for using CE-marked devices in Great Britain.
Great Britain also introduced strengthened post-market surveillance requirements that took effect on June 16, 2025.
An AI-generated “UK compliance package” that overlooks these distinctions can create gaps in market access planning and ongoing quality activities. The appropriate requirements must be assessed against the device, target market, and applicable route.
Under the EU Medical Device Regulation, manufacturers must maintain technical documentation and a QMS appropriate to their devices. The framework connects regulatory strategy, risk management, clinical evaluation, product realization, and post-market activities.
AI may help organize that documentation, but a convincing narrative cannot compensate for missing clinical evidence, unsupported equivalence claims, incomplete verification, or inconsistencies between risk controls and labeling.
For in vitro diagnostic devices, the separate IVDR framework requires its own assessment. Treating all devices as though the same requirements apply is precisely the kind of shortcut expert oversight must prevent.
One of the greatest risks of AI-generated quality documentation is the gap between what a procedure says and what employees actually do.
Imagine a generated procedure that promises quarterly supplier reviews, complaint escalation within a defined internal timeframe, and effectiveness checks for every corrective action. If those activities have not been assigned, resourced, and implemented, the company has created commitments it cannot demonstrate.
A functioning QMS needs:
AI can help draft the procedure. It cannot make the organization perform the work.
Experienced quality professionals help build a system proportionate to the business, its products, and its regulatory obligations. They also challenge procedures that look impressive but are impractical to maintain
Regulatory and quality documents can contain proprietary designs, source code, clinical information, supplier details, and confidential business plans.
Before uploading that information to an AI platform, companies should assess the platform’s contractual terms, access controls, retention practices, and permitted data uses. The assessment must reflect the specific service and configuration being used. NIST’s generative AI guidance identifies data privacy and information security among the risks organizations should manage.
Convenience should never become the default authorization to disclose sensitive information.
The practical approach is to give AI a defined supporting role and establish meaningful controls around its use.
Expert oversight must be substantive. A quick read for grammar is not a regulatory review.
The apparent savings from generating a submission or QMS quickly can disappear if the result requires extensive remediation, additional testing, or a revised regulatory strategy. More seriously, an overlooked gap can affect product quality and patient safety.
Manufacturers remain responsible for their products and compliance obligations. Using AI does not transfer that responsibility to the software provider, and hiring a consultant does not remove it either.
At RQMIS, we help medical device companies develop regulatory strategies, prepare and review submissions, and establish quality systems that reflect their products and operations. Our role is to connect the requirements to the evidence—and help teams identify gaps before those gaps become submission deficiencies or audit findings.
No consultant or AI tool can guarantee regulatory authorization. Qualified expertise can, however, help you build a defensible submission and a quality system your team can operate with confidence.
Before relying on AI-generated regulatory or quality documentation, have it evaluated by professionals who understand your device, your business, and your target markets. Contact RQMIS to discuss your submission readiness or QMS needs.